Search results for "OPD"

showing 10 items of 506 documents

Association between clusters of diseases and polypharmacy in hospitalized elderly patients: results from the REPOSI study.

2011

BACKGROUND: Although the association between multimorbidity and polypharmacy has been clearly documented, no study has analyzed whether or not specific combinations of diseases influence the prescription of polypharmacy in older persons. We assessed which clusters of diseases are associated with polypharmacy in acute-care elderly in-patients. METHODS: This cross-sectional study was held in 38 Italian internal medicine and geriatric wards participating in the Registro Politerapie SIMI (REPOSI) study during 2008. The study sample included 1155 in-patients aged 65 years or older. Clusters of diseases, defined as two or more co-occurring specific chronic diseases, were identified using the odds…

---Lung DiseasesMaleSettore MED/09 - Medicina InternaCross-sectional studyGastrointestinal DiseasesComorbidityRisk FactorsNeoplasmsPrevalenceCluster AnalysisHospitalized elderlyclustersGeriatricsAged 80 and overCOPDREPOSISettore MED/45 - Scienze Infermieristiche Generali Cliniche E PediatricheHospitalization---; clusters; polypharmacy; REPOSI; elderlyCardiovascular DiseasesFemalemedicine.medical_specialtyEndocrine System DiseaseselderlyCluster of diseasesInternal medicineDiabetes mellitusmedicineDiabetes MellitusInternal MedicineMultimorbidityHumansCluster of diseases; Hospitalized elderly; PolypharmacyAgedPolypharmacybusiness.industryPolypharmacy Cluster of diseases Hospitalized elderlyOdds ratiomedicine.diseaseComorbidityCross-Sectional StudiesLogistic ModelsGeriatricsPhysical therapyPolypharmacyDementiaMorbiditybusinessEuropean journal of internal medicine
researchProduct

Hexanoic Acid Treatment Prevents Systemic MNSV Movement in Cucumis melo Plants by Priming Callose Deposition Correlating SA and OPDA Accumulation

2017

Unlike fungal and bacterial diseases, no direct method is available to control viral diseases. The use of resistance-inducing compounds can be an alternative strategy for plant viruses. Here we studied the basal response of melon to Melon necrotic spot virus (MNSV) and demonstrated the efficacy of hexanoic acid (Hx) priming, which prevents the virus from systemically spreading. We analysed callose deposition and the hormonal profile and gene expression at the whole plant level. This allowed us to determine hormonal homeostasis in the melon roots, cotyledons, hypocotyls, stems and leaves involved in basal and hexanoic acid-induced resistance (Hx-IR) to MNSV. Our data indicate important roles…

0106 biological sciences0301 basic medicineMelonsalicylic acidPlant Sciencelcsh:Plant culture01 natural sciencesHypocotylMicrobiologyOPDA03 medical and health scienceschemistry.chemical_compoundCucumis meloPlant viruslcsh:SB1-1110Original ResearchHexanoic acidPriming by natural compoundsbiologyMelon necrotic spot virusCallosefood and beveragesSalicylic acidbiology.organism_classificationpriming by natural compounds030104 developmental biologychemistryBiochemistryMNSVhexanoic acidHexanoic acidCucumisSalicylic acid010606 plant biology & botany
researchProduct

Selective Inhibition of Phosphodiesterases 4A, B, C and D Isoforms in Chronic Respiratory Diseases: Current and Future Evidences

2016

Chronic respiratory diseases affect millions of people every day. According to the World Health Organization estimates, ~235 million people suffer from asthma, ~64 million suffer from chronic obstructive pulmonary disease (COPD), and millions more suffer from allergic rhinitis around the world. In recent last years, the first phosphodiesterase 4 (PDE4) inhibitor, roflumilast, was approved as a treatment to reduce the risk of exacerbations in stable and severe COPD associated with chronic bronchitis and a history of exacerbations. PDE4 exists as four subtypes (A, B, C, and D) each with a capacity to degrade cAMP, a second messenger involved in inflammatory responses. PDE4 inhibitors inhibit …

0301 basic medicineChronic bronchitisPhosphodiesterase InhibitorsPharmacologyPulmonary Disease Chronic Obstructive03 medical and health sciencesPDE4BDrug DiscoverymedicineAnimalsHumansRespiratory systemRoflumilastAsthmaPharmacologyCOPDPhosphoric Diester Hydrolasesbusiness.industryPhosphodiesterasemedicine.diseaseIsoenzymesDiarrhea030104 developmental biologymedicine.symptombusinessmedicine.drugCurrent Pharmaceutical Design
researchProduct

MUC1 deficiency mediates corticosteroid resistance in chronic obstructive pulmonary disease.

2018

Background Lung inflammation in COPD is poorly controlled by inhaled corticosteroids (ICS). Strategies to improve ICS efficacy or the search of biomarkers who may select those patients candidates to receive ICS in COPD are needed. Recent data indicate that MUC1 cytoplasmic tail (CT) membrane mucin can mediate corticosteroid efficacy in chronic rhinosinusitis. The objective of this work was to analyze the previously unexplored role of MUC1 on corticosteroid efficacy in COPD in vitro and in vivo models. Methods MUC1-CT expression was measured by real time PCR, western blot, immunohistochemistry and immunofluorescence. The inflammatory mediators IL-8, MMP9, GM-CSF and MIP3α were measured by EL…

0301 basic medicineMalemedicine.drug_classDrug ResistanceInflammationMUC1Corticosteroid resistancedigestive system03 medical and health sciencesMicePulmonary Disease Chronic Obstructive0302 clinical medicineGlucocorticoid receptorIn vivoAdrenal Cortex HormonesmedicineAnimalsHumansGene Silencingskin and connective tissue diseasesneoplasmsDexamethasoneMUC1Agedlcsh:RC705-779Mice KnockoutCOPDLungbusiness.industryResearchChronic obstructive pulmonary diseaseMucin-1Sputumlcsh:Diseases of the respiratory systemMiddle Agedmedicine.diseasedigestive system diseasesrespiratory tract diseasesMice Inbred C57BL030104 developmental biologymedicine.anatomical_structure030228 respiratory systemImmunologyCorticosteroidFemalemedicine.symptombusinessBiomarkersmedicine.drugRespiratory research
researchProduct

IL-17A-associated IKK-α signaling induced TSLP production in epithelial cells of COPD patients.

2018

Thymic stromal lymphopoietin (TSLP) is a cytokine expressed in the epithelium, involved in the pathogenesis of chronic disease. IL-17A regulates airway inflammation, oxidative stress, and reduction of steroid sensitivity in chronic obstructive pulmonary disease (COPD). TSLP and IL-17A were measured in induced sputum supernatants (ISs) from healthy controls (HC), healthy smokers (HS), and COPD patients by enzyme-linked immunosorbent assay. Human bronchial epithelial cell line (16HBE) and normal bronchial epithelial cells were stimulated with rhIL-17A or ISs from COPD patients to evaluate TSLP protein and mRNA expression. The effects of the depletion of IL-17A in ISs, an anticholinergic drug,…

0301 basic medicineMalemedicine.medical_treatmentClinical Biochemistrylcsh:MedicineCell CountBiochemistryCholinergic AntagonistsPathogenesisHistonesPulmonary Disease Chronic Obstructivelcsh:QD415-436COPDKinaseInterleukin-17AcetylationI-kappa B KinaseRespiratory Function TestsCytokinemedicine.anatomical_structureMolecular MedicineCytokinesFemaleProtein BindingSignal TransductionThymic stromal lymphopoietinEnzyme-Linked Immunosorbent AssayRespiratory MucosaArticleCell Linelcsh:Biochemistry03 medical and health sciencesThymic Stromal LymphopoietinmedicineGene silencingCOPDHumansMolecular Biologybusiness.industrylcsh:RSputumEpithelial Cellsmedicine.diseaseEpitheliumrespiratory tract diseases030104 developmental biologyCell cultureCancer researchbusinessBiomarkersExperimentalmolecular medicine
researchProduct

Mucoadhesive solid lipid microparticles for controlled release of a corticosteroid in the chronic obstructive pulmonary disease treatment.

2017

Therapeutic efficacy of inhaled drugs is limited by rapid clearance from the site of action due to absorption into systemic circulation or metabolic degradation by alveolar macrophages. Drug delivery systems offer new solutions to clinical problems especially in the treatment of pulmonary diseases. In particular, Solid Lipid Microparticles (SLM) in the range of 3-5 µm are suggested as systems for delivery of therapeutics to the lung as, because of their size, they are able to deposit into secondary bronchi, avoiding systemic absorption typical of alveolar regions. Here, we describe two novel different SLMs prepared with chitosan and alginate for sustained release of fluticasone propionate (…

0301 basic medicineMedicine (miscellaneous)Biocompatible Materials02 engineering and technologyPharmacologymedicine.disease_causeChitosanPulmonary Disease Chronic Obstructivechemistry.chemical_compoundDrug StabilityGlucuronic AcidAdrenal Cortex HormonesMucoadhesive Solid Lipid Nanoparticles (SLMs);Aerodynamic diameter;Chronic obstructive pulmonary disease (COPD)General Materials Sciencechronic obstructive pulmonary disease (COPD)LungChromatography High Pressure LiquidDrug CarriersHexuronic Acidsaerodynamic diameter; chronic obstructive pulmonary disease (COPD); mucoadhesive solid lipid microparticles (SLMs)021001 nanoscience & nanotechnologyLipidsControlled releasemucoadhesive solid lipid microparticles (SLMs)Microspheresmedicine.anatomical_structureDrug deliveryCorticosteroid0210 nano-technologymedicine.drugBiocompatibilityAlginatesCell SurvivalSurface Propertiesmedicine.drug_classBiomedical EngineeringBioengineeringDevelopmentFluticasone propionate03 medical and health sciencesAdministration InhalationmedicineHumansParticle Sizeaerodynamic diameterChitosanLungbusiness.industryEpithelial CellsDrug LiberationOxidative Stress030104 developmental biologychemistryDelayed-Action PreparationsImmunologyMicroscopy Electron ScanningFluticasonebusinessOxidative stress
researchProduct

Meta-analysis of exome array data identifies six novel genetic loci for lung function

2018

Background: Over 90 regions of the genome have been associated with lung function to date, many of which have also been implicated in chronic obstructive pulmonary disease. Methods: We carried out meta-analyses of exome array data and three lung function measures: forced expiratory volume in one second (FEV1), forced vital capacity (FVC) and the ratio of FEV1 to FVC (FEV1/FVC). These analyses by the SpiroMeta and CHARGE consortia included 60,749 individuals of European ancestry from 23 studies, and 7,721 individuals of African Ancestry from 5 studies in the discovery stage, with follow-up in up to 111,556 independent individuals. Results: We identified significant (P<2·8x10-7) associatio…

0301 basic medicineNonsynonymous substitutionVital capacityMedicine (miscellaneous)Genome-wide association studySingle-nucleotide polymorphismBiologyGenomeGeneral Biochemistry Genetics and Molecular Biologyhengityselimet03 medical and health sciencesFEV1/FVC ratio0302 clinical medicineMedicine and Health SciencesmedicineCOPDGWASkeuhkotExome030304 developmental biologyGenetics0303 health sciencesCOPDexome arrayta1184Lung function respiratory exome array GWAS COPDBiology and Life Sciencesta3141lung functionArticlesGenomicsta3121respiratory systemrespiratorymedicine.diseaserespiratory tract diseases030104 developmental biology030220 oncology & carcinogenesisExpression quantitative trait lociResearch Article
researchProduct

Impact of DLK1-DIO3 imprinted cluster hypomethylation in smoker patients with lung cancer.

2018

// Sonia Molina-Pinelo 1, 2 , Ana Salinas 1 , Nicolas Moreno-Mata 2 , Irene Ferrer 1, 2 , Rocio Suarez 1, 2 , Eduardo Andres-Leon 1 , Manuel Rodriguez-Paredes 4, 5 , Julian Gutekunst 4 , Eloisa Jantus-Lewintre 6, 7 , Carlos Camps 8, 9 , Amancio Carnero 1 , Luis Paz-Ares 1, 2 1 Instituto de Biomedicina de Sevilla (IBIS) (HUVR, CSIC, Universidad de Sevilla), Sevilla, Spain 2 Medical Oncology Department, Hospital Universitario Doce de Octubre & Centro Nacional de Investigaciones Oncologicas (CNIO), Madrid, Spain 3 Thoracic Surgery Department, Hospital Universitario Virgen del Rocio, Sevilla, Spain 4 Division of Epigenetics, DKFZ-ZMBH Alliance, German Cancer Research Center, Heidelberg, Germany…

0301 basic medicineOncologymedicine.medical_specialtyPathology03 medical and health sciences0302 clinical medicineInternal medicineCancer genomeMedicineCOPDIn patienttranscriptional regulationLung cancerGenome stabilityThoracic surgery departmentbusiness.industryDLK1-DIO3 clustermedicine.diseaselung cancer030104 developmental biologyOncologyNormal lung030220 oncology & carcinogenesisDNA methylationbusinessLung tissueepigeneticResearch Paper
researchProduct

2018

Background The expression and localization of transforming growth factor-β (TGF-β) pathway proteins in different compartments of the lower airways of patients with stable COPD is unclear. We aimed to determine TGF-β pathway protein expression in patients with stable COPD. Methods The expression and localization of TGF-β pathway components was measured in the bronchial mucosa and peripheral lungs of patients with stable COPD (n = 44), control smokers with normal lung function (n = 24), and control nonsmoking subjects (n = 11) using immunohistochemical analysis. Results TGF-β1, TGF-β3, and connective tissue growth factor expression were significantly decreased in the bronchiolar epithelium, w…

0301 basic medicinePulmonary and Respiratory MedicineLamina propriaCOPDmedicine.medical_specialtyLungbusiness.industryGrowth factormedicine.medical_treatmentConnective tissuerespiratory systemCritical Care and Intensive Care Medicinemedicine.diseaserespiratory tract diseasesCTGF03 medical and health sciences030104 developmental biologymedicine.anatomical_structureEndocrinologyInternal medicinemedicineBAMBIRespiratory systemCardiology and Cardiovascular MedicinebusinessChest
researchProduct

P285 The ‘real-life’ copd patient in the age of laba/lamas: an expansion of the daccord study

2016

Introduction The prospective, non-interventional DACCORD study collects data from a representative cohort of COPD out-patients across Germany who either initiated or changed COPD maintenance medication prior to entry. Initially, DACCORD consisted of two treatment groups (Glycopyrronium-based therapy vs. any other COPD maintenance medication with the exception of Glycopyrronium). Following the approval of LABA/LAMA fixed-dose combinations (FDC) in 2013, DACCORD was extended to follow an additional cohort of patients receiving any LABA/LAMA FDC over a period of 2 years. Methods 5223 patients with complete baseline data (3815 LAMA/LABA FDC vs. 1408 standard treatment group) were analysed here.…

0301 basic medicinePulmonary and Respiratory MedicinePediatricsmedicine.medical_specialtyeducation.field_of_studyCOPDExacerbationbiologybusiness.industryStandard treatmentPopulationLamamedicine.diseasebiology.organism_classificationObstructive lung disease03 medical and health sciences030104 developmental biology0302 clinical medicine030228 respiratory systemConcomitantCohortmedicineeducationbusinessThorax
researchProduct